Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report

Abstract

a case of 73-year-old patient with metastatic colorectal cancer who underwent trifluridine/tipiracil therapy within the Vi line was presented. Treatment with trifluridine/tipiracil allowed to achieve stabilization of the existing cancer for nearly 7 months.

Long-Term Survival in a Patient with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil as Late-Line Chemotherapy: A Case Report

“…The patient reported here had undergone multiple previous treatments with bevacizumab before taking part in the PRECONNECT study and receiving FTD/TPI. A previous case report describing long-term disease control with FTD/TPI in a 73-year-old patient with mCRC also reported anti-VEGF and anti-EGFR therapy use prior to treatment with FTD/TPI ( Table 2 ) [ 25 ]. An additional case study described a patient with mCRC who had received bevacizumab in previous lines of therapy who went on to maintain stable disease for more than 27 months with FTD/TPI third-line treatment ( Table 2 ) [ 15 ].…”